autologous blood and marrow transplantation - Blog Science ...

348 Chapter 6: Breast Cancer
re
>
'E
3
OT
0
1.0
0.9
0.8
0.7
0.6
9> 0.5
c
o
"55
0.4
% 0.3
§> 0.2
£ o.i
o . o
p=0.06
2 3 4 5
Years After Transplant
BM K-19PCR neg (n=15)
BM K-19PCR pos (n=24)
BM (n=34)
PB (n=78)
2 3 4 5 6 7 8
Years After Transplant
Figure 2. Negative prognostic factors for patients with stage II and III noninflammatory
breast cancer undergoing high-dose therapy and autologous stem cell transplant in the adjuvant
setting. A: presence or absence of K19 in the bone marrow; B: source of stem cells, bone
marrow vs. peripheral blood.
Although not previously described as a potential negative prognostic indicator,
it is of concern that patients receiving peripheral blood stem cells in the adjuvant
setting had a worse outcome than patients receiving autologous bone marrow. This
finding was not demonstrated in patients with metastatic breast cancer, suggesting
that the source of stem cells may not have been the only factor involved. Other